Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 691 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Safety and Preliminary Signs of Activity of OMO-103, a MYC Inhibitor,... February 9, 2024 Atlantic rowing trio smash world record and raise thousands for cancer... January 24, 2022 EMA Recommends Granting a Marketing Authorisation for Sacituzumab Govitecan October 25, 2021 Addressing Cancer Pain with Complementary Methods (Part 1) April 7, 2023 Load more HOT NEWS Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... A Lack of Resistance Gene Alterations in Baseline ctDNA Associated with... The American Rescue Act: What You Need to Know
